NCT04011787

Brief Summary

Patients with severe strokes are often unable to be take oral diet food and fluids safely because they cannot swallow effectively. Therefore, patients need to be fed via a tube placed through the nose into the stomach (nasogastric tube). Tube feeding can be given by the intermittent (bolus) method, whereby the feed is given over a short time (15 to 30 minutes), or by the continuous feeding method, where the feed is given continuously over 10-16 hours. Nasogastric feeding can be complicated by vomiting or reflux of the feed into the oesophagus causing aspiration of gastric contents into the lung and pneumonia. Nasogastric feeds can be given continuously or as bolus feeds. Healthy people eating normally take their diet in discrete meals. The human digestive system is adapted to intermittent food intake and is likely to work best if food is provided in this pattern, but the larger volume of the feed by this method may cause vomiting and aspiration. It is unclear which method is better for allowing normal digestive processes and reducing pneumonia due to aspirated feeds. There are no trials comparing these two feeding methods in patients with acute stroke. The aim of this small study is to determine if a trial comparing the two treatment approaches is feasible in patients with acute stroke, and to collect information on the effects on feed tolerance and digestion. In this study we will compare the effect of the bolus and intermittent nasogastric tube feeding on digestion and feed tolerance in 20 patients who need nasogastric feeding within 36 hours of a stroke. Patients will be randomly allocated to be given the feeds either by the bolus or by the continuous method for 7 days. During this time they will be examined every day. The study will examine how effectively food is digested by measuring the amount of feed given and the metabolic responses of the body by looking at changes in the level of blood sugar and digestive hormones. The investigators will also monitor complications such as vomiting, diarrhoea, and pneumonia. Patients will be randomly allocated to be given the feeds either by the bolus or by the continuous method for 7 days. This will provide information which will allow the investigators to design a larger definitive study to conclusively prove which method is more appropriate.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 12, 2019

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 8, 2019

Completed
3 years until next milestone

Study Start

First participant enrolled

July 1, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2023

Completed
Last Updated

May 26, 2022

Status Verified

May 1, 2022

Enrollment Period

1.1 years

First QC Date

March 12, 2019

Last Update Submit

May 19, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Feed tolerance

    Total of 7 points. 7/7 full tolerance, 0/7 severe intolerance. This is based on Nutrition, Vomiting, Diarrhoea, Bloating, Abdominal pain, Pneumonia and raised inflammatory markers

    7 days

Secondary Outcomes (15)

  • Number of glucose excursions above 7mmol/L

    7 days

  • mean glucose levels

    7 days

  • glucose centiles

    7 days

  • total area under curve (AUC)

    7 days

  • diurnal AUC

    7 days

  • +10 more secondary outcomes

Study Arms (2)

Intervention

ACTIVE COMPARATOR

bolus NGT feeding

Dietary Supplement: bolus NGT feedingDiagnostic Test: Continuous Glucose MonitoringDiagnostic Test: Metabolic ProfileRadiation: Chest X-ray

Control

OTHER

Continuous NGT feeding (standard care)

Dietary Supplement: Continuous NGT feedingDiagnostic Test: Metabolic ProfileRadiation: Chest X-ray

Interventions

bolus NGT feedingDIETARY_SUPPLEMENT

Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes

Intervention
Continuous NGT feedingDIETARY_SUPPLEMENT

Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol

Control

Both participant groups will have continuous glucose monitoring performed for 5 days while in the study

Intervention
Metabolic ProfileDIAGNOSTIC_TEST

Bloods will be taken to assess all patients metabolic profile

ControlIntervention
Chest X-rayRADIATION

A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia

ControlIntervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>=18 years
  • Within 36 h hospital admission with acute ischaemic or haemorrhagic stroke
  • Dysphagia requiring nasogastric tube (NGT) feeding (assessed by failed sip test)

You may not qualify if:

  • Moribund, receiving palliative care
  • Clinical diagnosis of pneumonia
  • Pre-existing gastric motility problems
  • Inability to obtain consent from the patients or their representative

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals of North Midlands NHS Trust

Stoke-on-Trent, Staffordshire, ST4 6QG, United Kingdom

Location

MeSH Terms

Conditions

StrokeDeglutition Disorders

Interventions

Continuous Glucose MonitoringMetabolomeX-Rays

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesEsophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesPharyngeal DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Blood Chemical AnalysisClinical Chemistry TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, EndocrineMonitoring, PhysiologicInvestigative TechniquesMetabolismElectromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaRadiationRadiation, Ionizing

Study Officials

  • Fahmy Hanna

    Consultant

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: 20 patients will be randomised to two arms with a control group of a further 10 patients
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2019

First Posted

July 8, 2019

Study Start

July 1, 2022

Primary Completion

August 1, 2023

Study Completion

September 1, 2023

Last Updated

May 26, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

The participants' clinicians clinical team and members of the research team on the delegation log will access the data. Representatives of the sponsor (UHNM) and representatives the regulatory authorities will have access to personal data for monitoring and audit purposes only.

Locations